Taipei consensus backs H pylori eradication as gastric cancer prevention strategy
The Taipei Global Consensus II gives Helicobacter pylori prevention a broad clinical mandate: screen where risk is highest, eradicate infection after detection, and confirm cure after treatment. Across 28 agreed statements, the panel framed H pylori not as a narrow infectious disease issue but as a central cancer-prevention target, because the organism remains the primary cause of gastric cancer and also drives peptic ulcer disease, ulcer recurrence, and NSAID- or aspirin-related ulcer complications.
A single point runs through the consensus with unusual clarity. Eradication works best before premalignant change has taken hold.
That timing matters at the cellular level. Once chronic infection has progressed into atrophy, intestinal metaplasia, or dysplasia, the biological terrain becomes less reversible even after the bacterium is cleared. Removing the inciting organism earlier interrupts the inflammatory cascade sooner, which is why the greatest cancer-risk reduction appears before premalignant conditions emerge.
Risk reduction extends across age groups, but screening should stay selective
The consensus states that H pylori eradication reduces gastric cancer risk across all age groups. Adults at every stage can benefit, yet the panel did not turn that finding into a one-size-fits-all screening imperative. Instead, screening should prioritize populations at higher gastric cancer risk, where the balance between benefit, implementation burden, and resource use is most favorable.
That approach fits the epidemiology of H pylori. Infection is common, but gastric cancer risk is concentrated in subgroups shaped by geography, family clustering, prior mucosal injury, and other host or environmental factors. In practical terms, broad eradication policy and targeted screening are not competing ideas; they operate at different points in the prevention pathway. Eradication can be offered to all infected adults, while screening strategies can be calibrated to local cancer incidence and patient-level risk.
The panel also affirmed that H pylori transmission occurs mainly within families. Family-based approaches therefore deserve more attention, not only because they may reduce spread, but because shared exposure patterns can undermine single-patient treatment when household reservoirs remain untreated. Preventing reinfection and repeated transmission is especially relevant in settings where prevalence remains high and where clusters of infection persist across generations.
Test selection favors breath and stool assays, with serology reserved for specific settings
For active infection testing, the preferred tools are the 13C-urea breath test and monoclonal stool antigen tests. Both detect current infection and are suited to screening pathways that need reliable noninvasive confirmation. Validated serology can still serve as a feasible alternative in low-prevalence settings, but only when followed by confirmatory non-serologic testing. Antibody positivity alone cannot distinguish past exposure from active infection, which limits its usefulness when treatment decisions depend on current colonization status.
This diagnostic sequence is clinically important because screening programs fail when the test strategy and treatment strategy are misaligned. A program that identifies more people but cannot distinguish active infection from remote exposure will waste antibiotics, increase follow-up confusion, and dilute the value of eradication efforts. The consensus therefore places confirmatory testing at the center of the pathway, not as an administrative afterthought but as part of the therapeutic contract.
Integrating H pylori screening into existing health programs may improve adherence and use of resources. Embedding testing in established care pathways can lower logistical barriers, especially in populations that already encounter the health system through other preventive or chronic disease services. For public health planners, that may be the most realistic route to broad uptake without building a separate infrastructure from scratch.
Resistance-aware eradication favors empiric bismuth quadruple therapy in high-resistance regions
Treatment choice must now account for antibiotic resistance. In regions where conventional antibiotics face high H pylori resistance, the consensus recommends empiric eradication treatment, especially bismuth quadruple therapy. Potassium competitive acid blocker-based regimens are named as alternatives.
The logic is straightforward: if resistance patterns are unfavorable, waiting for a perfect susceptibility profile can delay treatment and allow ongoing inflammation to persist. An empiric regimen that performs reliably against resistant strains is more likely to achieve the core goal of eradication, which is the point at which cancer prevention and ulcer prevention begin to diverge from theoretical promise and enter routine care.
Confirmatory testing after treatment is strongly recommended to document eradication. This is not a symbolic step. Persistent infection after therapy means persistent carcinogenic exposure, persistent ulcer risk, and the possibility of falsely assuming the patient is protected. Cure should be proven, not presumed.
Ulcer prevention, reflux safety, and the need for longer-term stewardship
Beyond cancer prevention, the consensus reinforces H pylori eradication as a preventive strategy for peptic ulcer disease. It promotes ulcer healing, prevents ulcer recurrence, and reduces the risk of NSAID- and aspirin-related ulcers. For patients who require antiplatelet or anti-inflammatory therapy, this adds a meaningful layer of protection.
The panel also states that eradication does not increase the risk of reflux oesophageal adenocarcinoma. That finding matters because one recurring concern in H pylori management has been whether removing the organism might shift gastric physiology in a way that worsens downstream esophageal risk. The consensus does not support that fear as a reason to avoid treatment.
Endoscopy for high-risk infection and alarm features
Endoscopy is suggested for H pylori-infected individuals with a high risk of gastric cancer or with alarm features. This recommendation preserves the role of mucosal visualization where the probability of established pathology is higher or where symptoms raise concern for more advanced disease. Screening and eradication can reduce future risk, but they do not replace diagnostic evaluation when clinical red flags are already present.
Research gaps remain centered on timing, durability, and precision risk stratification
The consensus closes by identifying several unresolved issues. Long-term disruptions to the microbiota and resistome need further study, especially as antibiotic exposure expands. The environmental impact of broader antibiotic use also deserves attention. A vaccine remains an unmet need. So does a more precise risk-stratified framework informed by advanced genetic research.
Future work will need to determine the optimal timing for screening and to measure long-term individual and population outcomes, not just short-term eradication success. The clinical question is no longer whether H pylori can be removed. It is how to identify the right people at the right time, with the right test and the right regimen, before premalignant change narrows the benefit of prevention.